Table of Contents for New Drug Futures: Vaccines Chapter
CURRENT MARKET SIZE 1
Vaccine Sales breakdown and forecasts 3
ADDRESSABLE PATIENT POPULATION 4
PAEDIATRIC VACCINES 5
ROTAVIRUS 5
ADULT VACCINES 6
ZOSTER VIRUS 6
CERVICAL CANCER VACCINES 7
LUNG CANCER VACCINES 8
PROSTATE CANCER VACCINES 9
CURRENT TREATMENTS 10
VACCINE SALES DRIVERS 11
VACCINE SALES BREAKERS 12
FUTURE TREATMENTS 13
MARKET DYNAMICS - WINNERS & LOSERS 20
KEY VACCINE LAUNCHES BY 2010 21
KEY EVALUATION CRITERIA 22
KEY VACCINE LAUNCHES BY 2010 23
Cervarix (GlaxoSmithKline/MedImmune) 23
Novelty/rationale for mechanism of action 23
Proof of concept/clinical data 23
Management / clinical expertise 24
Competition within the marketplace/gaining share of voice 24
Risks associated with developing a drug within a therapeutic class 24
Filings & Approvals 24
Sales forecasts and assumptions 25
Competitor Ratio Analysis 25
Gardasil (Merck & Co/sanofi pasteur) 25
Novelty/rationale for mechanism of action 25
Proof of concept/clinical data 25
Management / clinical expertise 26
Competition within the marketplace/gaining share of voice 26
Risks associated with developing a drug within a therapeutic class 26
Filings & Approvals 27
Sales forecasts and assumptions 27
Competitor Ratio Analysis 27
GVAX (Cell Genesys) 27
Novelty/rationale for mechanism of action 27
Proof of concept/clinical data 28
Management/clinical expertise 28
Competition within the marketplace/gaining share of voice 29
Risks associated with developing a drug within a therapeutic class 29
Filings and approval 29
Sales forecasts and assumptions 29
Competitor Ratio Analysis 30
L-BLP25 (Biomira/Merck KGaA) 30
Novelty/rationale for mechanism of action 30
Proof of concept/clinical data 30
Management/clinical expertise 31
Competition within the marketplace/gaining share of Voice 31
Risks associated with developing a drug within a therapeutic class 31
Filings & Approvals 31
Sales forecasts and assumptions 32
Competitor Ratio Analysis 32
Provenge (Dendreon) 33
Novelty/rationale for mechanism of action 33
Proof of concept/clinical data 33
Management/clinical expertise 34
Competition within the marketplace/gaining share of voice 34
Risks associated with developing a drug within a therapeutic class 34
Filings and approval 35
Sales forecasts and assumptions 35
Competitor Ratio Analysis 35
Rotarix (GlaxoSmithKline/Avant Immunotherapeutics) 36
Novelty/rationale for mechanism of action 36
Proof of concept/clinical data 36
Management and clinical expertise 36
Competition within the marketplace/ gaining share of voice 36
Risks associated with developing a drug within a therapeutic class 37
Filings & Approvals 37
Sales forecasts and assumptions 37
Competitor Ratio Analysis 38
Rotateq (Merck & Co.) 38
Novelty/rationale for mechanism of action 38
Proof of concept/clinical data 38
Management and clinical expertise 38
Competition within the marketplace/ gaining share of voice 39
Risks associated with developing a drug within a therapeutic class 39
Filings & Approvals 39
Sales forecasts and assumptions 39
Competitor Ratio Analysis 40
Streptorix (GlaxoSmithKline/MedImmune) 40
Novelty/rationale for mechanism of action 40
Proof of concept/clinical data 40
Management/clinical expertise 41
Competition within the marketplace/gaining share of voice 41
Risks associated with developing a drug within a therapeutic class 41
Filings and approval 41
Sales forecasts and assumptions 42
Competitor Ratio Analysis 42
Zostavax (Merck & Co.) 43
Novelty/rationale for mechanism of action 43
Proof of concept/clinical data 43
Management / clinical expertise 43
Competition within the marketplace/gaining share of voice 43
Filings & Approvals 44
Sales forecasts and assumptions 44
Competitor Ratio Analysis 44
COMPETITOR RATIO ANALYSIS SUMMARY 45
COMPETITOR RATIO ANALYSIS – VACCINES 46
COMPETITOR RATIO ANALYSIS - COMPANIES 48
CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: keithw@cmsinfo.com
copyright © 2005 all rights reserved
For more information about us, visit CMSinfo.
